#1 Clinical Trials Search in Europe

Cenobamate

Cenobamate is an emerging anti-seizure medication that has shown promise in treating various forms of epilepsy, particularly partial-onset (focal) seizures. This article explores the ongoing clinical trials investigating the efficacy, safety, and potential applications of cenobamate in epilepsy treatment.

Table of Contents

What is Cenobamate?

Cenobamate, also known by its research name YKP3089, is a new anti-epileptic drug (AED) that has been approved for use in several countries, including the United States and Europe[1]. It is a small molecule medication designed to treat epilepsy, particularly partial-onset seizures (also called focal seizures) in adults[1]. Partial-onset seizures are a type of epileptic seizure that starts in one area of the brain.

How Cenobamate Works

While the exact mechanism of action is not fully understood, cenobamate is believed to work by reducing the abnormal electrical activity in the brain that causes seizures. It does this by interacting with certain channels in brain cells that control the flow of electrical signals[1].

Conditions Treated by Cenobamate

Cenobamate is primarily used to treat the following conditions:

  • Partial-onset seizures (focal seizures): These are seizures that start in one area of the brain[1].
  • Primary generalized tonic-clonic seizures (PGTC): These are seizures that affect the entire brain from the start[2].
  • Idiopathic generalized epilepsy: This is a type of epilepsy with no known cause[2].

How Cenobamate is Administered

Cenobamate is typically taken orally once daily, either in the morning or evening, with or without food[2]. The dosage is usually started low and gradually increased over several weeks to reach the target dose. This approach, known as titration, helps minimize side effects[1].

For adults, cenobamate is available in tablet form. For adolescents, it may be given as an oral suspension, with the dose adjusted based on the patient’s weight[2].

Efficacy of Cenobamate

Clinical trials have shown promising results for cenobamate in treating epilepsy:

  • In studies of partial-onset seizures, a significant number of patients achieved seizure freedom (no seizures) during treatment with cenobamate[1].
  • For primary generalized tonic-clonic seizures, cenobamate has shown potential in reducing seizure frequency[2].

Safety and Side Effects

As with all medications, cenobamate can cause side effects. Common side effects may include:

  • Sleepiness or drowsiness
  • Dizziness
  • Fatigue
  • Balance problems

In rare cases, a serious condition called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been reported. This is a type of severe allergic reaction that requires immediate medical attention[3].

Patients taking cenobamate are closely monitored for side effects, and regular blood tests may be performed to ensure safety[4].

Ongoing Research

Several clinical trials are currently underway to further investigate the use of cenobamate:

  • Studies are exploring its use as a monotherapy (used alone) for newly diagnosed epilepsy[1].
  • Research is being conducted on its effectiveness in treating primary generalized tonic-clonic seizures[2].
  • Investigations are ongoing regarding its use in patients with liver problems[5].
  • Studies are examining its long-term safety and efficacy[4].
  • Research is being conducted on its use in intensive care settings for acute, frequent seizures and status epilepticus (a prolonged seizure or series of seizures without full recovery between them)[3].

These ongoing studies aim to provide more information about cenobamate’s effectiveness, safety, and potential uses in different patient populations and clinical scenarios.

Aspect Details
Primary Indications Partial-onset seizures (focal seizures), primary generalized tonic-clonic seizures
Dosage Range 100 mg to 400 mg per day, typically started at lower doses and titrated up
Administration Oral, once daily
Trial Designs Open-label, double-blind, placebo-controlled, randomized
Key Outcomes Measured Seizure frequency reduction, responder rates, safety and tolerability, quality of life
Special Populations Studied Patients with hepatic impairment, newly diagnosed epilepsy, drug-resistant epilepsy
Safety Monitoring Adverse events, laboratory tests, ECG, vital signs, DRESS syndrome risk
Long-term Studies Several trials include extension phases to assess long-term efficacy and safety

FAQ

  • What is cenobamate? Cenobamate is a small molecule medication approved in several countries for treating partial-onset (focal) seizures in adults with epilepsy. It works to reduce the frequency and severity of seizures.
  • What types of seizures is cenobamate being studied for? Cenobamate is primarily being studied for partial-onset seizures (focal seizures), but some trials are also investigating its use in primary generalized tonic-clonic seizures and other forms of epilepsy.
  • How is cenobamate administered in clinical trials? In most trials, cenobamate is administered orally once daily. The dosage typically starts low and is gradually increased over several weeks to reach the target dose, which can range from 100 mg to 400 mg per day.
  • What are the main goals of cenobamate clinical trials? The main goals are to evaluate the efficacy of cenobamate in reducing seizure frequency, assess its safety and tolerability, determine optimal dosing regimens, and investigate its long-term effects in patients with epilepsy.
  • Are there any special considerations for cenobamate use? Yes, some trials are investigating cenobamate's use in specific populations, such as patients with hepatic impairment. Additionally, researchers are monitoring for potential side effects, including a rare but serious condition called DRESS syndrome.

Ongoing Clinical Trials on Cenobamate

  • Study of Cenobamate for Children with Partial-Onset Seizures

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Hungary Spain

  • Study on the Safety and Effectiveness of Cenobamate for Children with Focal Seizures

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Poland Spain

  • Study on the Long-term Safety of Cenobamate for Patients with Primary Generalized Tonic-Clonic Seizures

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Poland Slovakia Spain

  • Study on the Effectiveness and Safety of Cenobamate for Patients Aged 12 and Older with Primary Generalized Tonic-Clonic Seizures

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Poland Slovakia Spain

Glossary

  • Partial-onset seizures (POS): Also known as focal seizures, these are seizures that start in one area of the brain. They can be simple (without loss of awareness) or complex (with altered awareness).
  • Adjunctive therapy: Treatment given in addition to the primary or initial therapy to maximize its effectiveness. In epilepsy, it often refers to adding a new anti-seizure medication to existing treatments.
  • Monotherapy: The use of a single drug to treat a particular condition. In epilepsy, it refers to using only one anti-seizure medication.
  • Titration: The process of gradually adjusting the dose of a medication until the optimal dose is reached. This is often done to minimize side effects while achieving therapeutic benefits.
  • Maintenance Phase: The period in a clinical trial when participants receive a stable dose of the study medication after the initial titration period.
  • DRESS syndrome: Drug Reaction with Eosinophilia and Systemic Symptoms, a rare but serious adverse drug reaction that can occur with some medications, including anti-epileptic drugs.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being administered.
  • Double-blind study: A clinical trial design where neither the participants nor the researchers know who is receiving the study drug or placebo.
  • Responder rate: The percentage of participants in a clinical trial who achieve a predefined level of improvement, often a 50% or greater reduction in seizure frequency.

References

  1. https://clinicaltrials.gov/study/NCT06453213
  2. https://clinicaltrials.gov/study/NCT03678753
  3. https://clinicaltrials.gov/study/NCT06352723
  4. https://clinicaltrials.gov/study/NCT06590896
  5. https://clinicaltrials.gov/study/NCT04791553